Results 71 to 80 of about 31,065 (253)

Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health inequity may be contributing to imprecise dose predictions for CYP2D6‐metabolizing drugs.
Oyinlade Kehinde, Samuel E. Vaughn, Ogochukwu Amaeze, Paul Toren, Brandon Retke, Akinyemi Oni‐Orisan, Laura B. Ramsey   +6 more
wiley   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Quinidine Therapy for Lennox-Gastaut Syndrome With KCNT1 Mutation. A Case Report and Literature Review

Frontiers in Neurology, 2019
Mutations in the Potassium channel subfamily T member 1 (KCNT1) gene have been reported in a range of epileptic encephalopathies. Here we report the case of a 12-year-old male suffering from multiple types of epileptic seizures and cognitive decline from
Yu Jia, Yu Jia, Yicong Lin, Yicong Lin, Jing Li, Jing Li, Mingyu Li, Mingyu Li, Yifan Zhang, Yifan Zhang, Yue Hou, Yue Hou, Aihua Liu, Aihua Liu, Liping Zhang, Liping Li, Liping Li, Peng Xiang, Peng Xiang, Jing Ye, Jing Ye, Zhaoyang Huang, Zhaoyang Huang, Yuping Wang, Yuping Wang   +24 more
doaj   +1 more source

In Silico Screening and Designing Synthesis of Cinchona Alkaloids Derivatives as Potential Anticancer [PDF]

, 2017
P-glycoprotein (P-gp) resistance in cancer cells decreases intracellular accumulation of various anticancer drugs. This multidrug resistance (MDR) protein can be modulated by a number of non-cytotoxic drugs.
Hanafi, M. (Muhammad), Prasasty, V. D. (Vivitri), Primahana, G. (Gian), Rosmalena, R. (Rosmalena), Udin, L. Z. (Linar)   +4 more
core   +2 more sources

Evaluation of propranolol and quinidine in the treatment of quinidine-resistant arrhythmias [PDF]

The American Journal of Cardiology, 1971
Abstract Combining propranolol and quinidine should improve the antiarrhythmic action of quinidine by blocking beta adrenergic receptors, an action helpful in cases of arrhythmias associated with anesthetic agents, digitalis and stress. To test this hypothesis, 60 patients with paroxysmal arrhythmias resistant to quinidine and 17 with chronic atrial ...
Fors, Jr. , William J., Vander Ark, Condon R., Reynolds, Jr. , Ernest W.   +2 more
openaire   +4 more sources

In silico Assessment of Pharmacotherapy for Human Atrial Patho-Electrophysiology Associated With hERG-Linked Short QT Syndrome

Frontiers in Physiology, 2019
Short QT syndrome variant 1 (SQT1) arises due to gain-of-function mutations to the human Ether-à-go-go-Related Gene (hERG), which encodes the α subunit of channels carrying rapid delayed rectifier potassium current, IKr.
Dominic G. Whittaker, Dominic G. Whittaker, Jules C. Hancox, Jules C. Hancox, Henggui Zhang, Henggui Zhang, Henggui Zhang, Henggui Zhang   +7 more
doaj   +1 more source

Role of pharmacotherapy in Brugada syndrome [PDF]

, 2004
In patients who undergo aborted sudden cardiac death or syncope of unknown origin (symptomatic Brugada syndrome), no one argues that the implantation of an ICD is the first-line therapy regardless of the findings of the EP study.
Tsuchiya, Takeshi
core   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

Dextromethorphan versus Dextrorphan: A Quantitative Comparison of Antitussive Potency following Separate Administration of Metabolite

The Journal of Clinical Pharmacology, EarlyView.
Abstract To assess the antitussive effects of dextrorphan (DOR) relative to its parent compound, dextromethorphan (DEX) a double‐blind, randomized, placebo‐controlled crossover study was conducted in 23 healthy volunteers using citric acid cough challenge test after administering placebo, DEX, or DOR.
Saeed Rezaee, Caroline E. Wright, Alyn H. Morice, Amin Rostami‐Hodjegan   +3 more
wiley   +1 more source

Quinoline Alkaloids in Suspension Cultures of Cinchona ledgeriana Treated with Various Substances

Hayati Journal of Biosciences, 2010
Cinchona alkaloids are in extensive uses, not only for drugs but also for soft drink industries. They are harvested from the bark of trees Cinchona spp. after certain ages and therefore are available over a limited time.
DIAH RATNADEWI, SUMARYONO
doaj   +3 more sources